CMPX Compass Therapeutics
Price Chart
Executive Summary
Compass Therapeutics announced that tovecimig, in combination with paclitaxel, achieved a highly statistically significant improvement in progression-free survival (PFS) in the COMPANION-002 trial for second-line biliary tract cancer, with median PFS of 4.7 months vs. 2.6 months (HR=0.44, p<0.0001). While overall survival (OS) did not meet statistical significance due to high crossover (54%), post hoc analyses showed crossover patients had markedly improved OS (12.8 vs. 6.1 months). The company plans to meet with the FDA ahead of a Biologics License Application (BLA) submission.
Actionable Insight
The strong PFS data and compelling crossover survival signal support a viable BLA path despite the OS miss; traders should monitor the upcoming FDA meeting for feedback on accelerated approval potential. A positive readout could trigger significant upside given the high unmet need and lack of competition in second-line BTC.
Key Facts
- Tovecimig + paclitaxel improved median PFS to 4.7 months vs. 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), a 56% reduction in progression risk.
- OS did not reach statistical significance due to 54% crossover from control arm to tovecimig, confounding the analysis.
- Post hoc analysis showed crossover patients had median OS of 12.8 months vs. 6.1 months for non-crossover patients (HR=0.54, p=0.04).
- Primary endpoint of ORR was previously met: 17.1% vs. 5.3% (p=0.031).
- 85% of all study patients received tovecimig, with a pooled median OS of 8.9 months, above historical benchmarks of ~6 months.
- Safety profile was consistent with prior data; most common Grade ≥3 AEs were hypertension (44%) and neutropenia (36%).
- No FDA-approved therapy exists for second-line BTC without actionable mutations, creating significant unmet need.
Financial Impact
Potential blockbuster opportunity in a rare cancer with no approved second-line therapy; peak sales estimates could exceed $500M annually if approved.
Risk Factors
- FDA may require additional data or a confirmatory trial before granting approval, especially given the OS non-significance.
- High crossover complicates interpretation of OS, which could be a point of contention during regulatory review.
- Competition may emerge from other late-stage targeted therapies or immunotherapies in BTC.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281512 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 5, 2026
15d ago
|
8-K
| $1.95 $1.83 | ▼ −6.15% | ▼ −8.14% | $1.89 (−3.08%) |
|
Apr 29, 2026
21d ago
|
DEFA14A
| $1.67 $1.95 | ▲ +16.77% | ▲ +13.66% | $1.89 (+13.17%) |
|
Apr 27, 2026
23d ago
|
8-K
| $1.79 $1.94 | ▲ +8.38% | ▲ +7.98% | $1.89 (+5.59%) |
|
Apr 27, 2026
23d ago
|
Press Release
| $1.79 $1.94 | ▲ +8.38% | ▲ +7.98% | $1.89 (+5.59%) |
|
Apr 24, 2026
26d ago
|
Press Release
| $1.79 $1.94 | ▲ +8.38% | ▲ +7.98% | $1.89 (+5.59%) |
|
Mar 5, 2026
10w ago
|
8-K / PRESS-RELEASE
| $5.53 $5.19 | ▼ −6.15% | ▼ −3.91% | $1.89 (−65.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access